Recent events have seen Moderna facing both highs and lows in the biotech market. The firm had filed an updated COVID vaccine for review, however, faced challenges with its combo flu-COVID vaccine, causing it to withdraw its licensing submission. This decision came as the FDA expanded warnings of heart risk in young males linked with COVID vaccines, impacting both Moderna and its competitor, Pfizer/BioNTech. Simultaneously, Moderna also began the first US dosage in phase 1 of testing mRNA-4106 for solid tumours.
Furthermore, the company has experienced ups and downs in its stock trade, with certain instances leading to a crash, while others indicated a strong rally. Also notable are Moderna's advancements in pandemic preparedness with clearance for a commercial mRNA vaccine plant in the UK and a $590 million grant from HHS to develop mRNA vaccines against pandemic flu threats. Despite setbacks, Moderna seeks to accelerate the development of other mRNA-based vaccines, such as the bird flu vaccine, and broaden the potential applications of mRNA technologies, presenting promising innovation.
Moderna MRNA News Analytics from Thu, 29 Aug 2024 07:00:00 GMT to Sat, 24 May 2025 08:51:24 GMT - Rating -2 - Innovation +5 - Information +6 - Rumor +1
